Development of a protein therapeutics to counteract mustard-induced skin injury
开发蛋白质疗法来对抗芥末引起的皮肤损伤
基本信息
- 批准号:10667433
- 负责人:
- 金额:$ 19.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-01 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AblationAlkylating AgentsAnimal ModelBlood CirculationBullaCell membraneCellsCellular MembraneCellular StructuresCessation of lifeChemical WarfareChemistryChronicClinical ResearchCreamCutaneousDNA DamageDataDermalDevelopmentDoseEpidermisEventExposure toFormulationFree Radical FormationFutureGenesHair follicle structureHistologicHumanImmobilizationImpairmentInflammationInjuryIntramuscularKnowledgeLesionLinkLipid PeroxidationLongevityMechlorethamineMedicalMembraneMovementMulticellular ProcessMusMustardMustard GasOrganOxidative StressOxidative Stress InductionPathologyPenetrationPilot ProjectsPlayPredispositionProcessProteinsReagentRecombinantsRegenerative capacityRejuvenationResearch PersonnelResistanceRoleSiteSkinSkin injuryTherapeuticTimeTissuesTopical applicationToxic effectTransgenic MiceUlcerVesicantsWild Type Mousecombatdermal exposurehealinginjury and repairkeratinocytelipophilicitylive cell imagingmanufacturemanufacturing scale-upmouse modelnovelnovel therapeuticsoverexpressionpre-clinicalpreservationprototyperepair functionrepairedskin woundstem cell functionstem cellssuccesstherapeutic developmenttherapeutic proteintissue injurywound healing
项目摘要
PROJECT SUMMARY
Sulfur mustard (SM) and nitrogen mustard (NM) are vesicant agents that cause blistering of the skin. As
alkylating agents, SM/NM causes skin injuries through complicated cellular events, involving DNA damage, free
radical formation, and lipid peroxidation. Development of therapeutic approaches that target the multi-cellular
process of tissue injury-repair can potentially provide effective countermeasures to combat vesicant-induced
dermal lesions. Our group previously identified MG53 as an essential component of cell membrane repair.
Compared with the wild type mice, the mg53-/- mice show increased susceptibility to NM-induced dermal injuries,
whereas transgenic mice with overexpression of MG53 are resistant to dermal exposure of NM. Using live-cell
imaging, we made an unexpected and potentially exciting finding that in human follicle stem cells (HFSCs)
treated with NM, the intrinsic membrane repair function of MG53 was compromised. However, the application of
exogenous recombinant human MG53 (rhMG53) protein could restore cell membrane integrity from NM-induced
injury in both keratinocytes and HFSCs. We have generated preliminary data to show that topical administration
of rhMG53 can mitigate NM-induced dermal injury in mice. Studies proposed in this Exploratory and
Developmental R21 project are focused on understanding the mechanistic action of MG53 in skin wound repair
following NM exposure (Aim 1), and establishing the efficacious dose and effective time window for rhMG53
application to treat NM-induced skin injuries in mice (Aim 2). Pending on positive findings from this R21 project,
we plan to submit a larger CounterACT U01 application to further build the proof-of-concept data in large animal
models of SM-induced cutaneous injury, and to seek partnership with FDA and BARDA for advancing rhMG53
as a novel protein therapeutic that can be stockpiled as a medical reserve to treat cutaneous (and other organs)
injuries in the event of chemical warfare.
项目摘要
硫芥(SM)和氮芥(NM)是引起皮肤起泡的起泡剂。作为
烷化剂SM/NM通过复杂的细胞事件引起皮肤损伤,涉及DNA损伤,游离
自由基形成和脂质过氧化。靶向多细胞肿瘤的治疗方法的发展
组织损伤修复过程可以潜在地提供有效的对策,以对抗水疱剂引起的
皮肤损伤我们的小组先前确定MG 53是细胞膜修复的重要组成部分。
与野生型小鼠相比,mg 53-/-小鼠对NM诱导的皮肤损伤表现出增加的易感性,
而MG 53过表达的转基因小鼠对NM的皮肤暴露具有抗性。使用活细胞
通过成像,我们发现了一个意想不到的和潜在的令人兴奋的发现,在人类卵泡干细胞(HFSC)中,
经NM处理后,MG 53的内在膜修复功能受损。然而,应用
外源性重组人MG 53蛋白(rhMG 53)可以恢复NM诱导的细胞膜完整性,
角质形成细胞和HFSC两者的损伤。我们已经生成了初步数据,表明局部给药
rhMG 53能减轻NM诱导的小鼠皮肤损伤。本探索性研究中提出的研究,
开发R21项目的重点是了解MG 53在皮肤伤口修复中的机制作用
NM暴露后(目标1),并确定rhMG 53的有效剂量和有效时间窗
应用于治疗小鼠中NM诱导的皮肤损伤(目的2)。在R21项目取得积极成果之前,
我们计划提交更大的CounterACT U 01申请,以进一步构建大型动物的概念验证数据
SM诱导的皮肤损伤模型,并寻求与FDA和巴尔达的合作,以推进rhMG 53
作为一种新型蛋白质治疗药物,可以储存作为医疗储备来治疗皮肤(和其他器官)
在化学战中受伤。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Sustained delivery of rhMG53 promotes diabetic wound healing and hair follicle development.
- DOI:10.1016/j.bioactmat.2022.03.017
- 发表时间:2022-12
- 期刊:
- 影响因子:18.9
- 作者:Niu H;Li H;Guan Y;Zhou X;Li Z;Zhao SL;Chen P;Tan T;Zhu H;Bergdall V;Xu X;Ma J;Guan J
- 通讯作者:Guan J
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Haichang Li其他文献
Haichang Li的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Haichang Li', 18)}}的其他基金
Development of a protein therapeutics to counteract mustard-induced skin injury
开发蛋白质疗法来对抗芥末引起的皮肤损伤
- 批准号:
10410842 - 财政年份:2022
- 资助金额:
$ 19.69万 - 项目类别:
相似海外基金
Differential resistance mechanisms to monofunctional vs bifunctional alkylating agents in glioma
神经胶质瘤对单功能烷化剂与双功能烷化剂的不同耐药机制
- 批准号:
10374792 - 财政年份:2021
- 资助金额:
$ 19.69万 - 项目类别:
Elucidation and prevention of the mechanism of hepatic sinusoidal obstruction syndrome (SOS) induced by DNA alkylating agents
DNA烷化剂诱发肝窦阻塞综合征(SOS)机制的阐明和预防
- 批准号:
21K15255 - 财政年份:2021
- 资助金额:
$ 19.69万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Differential resistance mechanisms to monofunctional vs bifunctional alkylating agents in glioma
神经胶质瘤对单功能烷化剂与双功能烷化剂的不同耐药机制
- 批准号:
10570900 - 财政年份:2021
- 资助金额:
$ 19.69万 - 项目类别:
Development of individualized therapy by elucidation of molecular mechanisms for hypermutation phenotype induced by treatment with alkylating agents in glioma
通过阐明神经胶质瘤中烷化剂治疗诱导的超突变表型的分子机制来开发个体化治疗
- 批准号:
18K09004 - 财政年份:2018
- 资助金额:
$ 19.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Reversing intrinsic cancer cell resistance to alkylating agents by histone deacetylase inhibition
通过组蛋白脱乙酰酶抑制逆转癌细胞对烷化剂的内在耐药性
- 批准号:
214657440 - 财政年份:2012
- 资助金额:
$ 19.69万 - 项目类别:
Research Grants
Rerouting alkylating agents to the mitochondria for cancer therapy
将烷化剂重新路由至线粒体用于癌症治疗
- 批准号:
247842 - 财政年份:2011
- 资助金额:
$ 19.69万 - 项目类别:
Studentship Programs
Novel approaches to enhance tumor cell cytotoxicity of alkylating agents
增强烷化剂肿瘤细胞细胞毒性的新方法
- 批准号:
8105413 - 财政年份:2010
- 资助金额:
$ 19.69万 - 项目类别:
Novel approaches to enhance tumor cell cytotoxicity of alkylating agents
增强烷化剂肿瘤细胞细胞毒性的新方法
- 批准号:
8271313 - 财政年份:2010
- 资助金额:
$ 19.69万 - 项目类别:
Novel approaches to enhance tumor cell cytotoxicity of alkylating agents
增强烷化剂肿瘤细胞细胞毒性的新方法
- 批准号:
8730259 - 财政年份:2010
- 资助金额:
$ 19.69万 - 项目类别:
Novel approaches to enhance tumor cell cytotoxicity of alkylating agents
增强烷化剂肿瘤细胞细胞毒性的新方法
- 批准号:
8676463 - 财政年份:2010
- 资助金额:
$ 19.69万 - 项目类别: